Buy Amoxicillin

A combination of two FDA-approved drugs, already approved for fighting other bacterial infections, shows potential for treating extensively drug resistant tuberculosis (XDR-TB), the most deadly form of the infection.

This finding is reported by scientists from Albert Einstein College of Medicine of Yeshiva University in the February 27 issue of Science .

TB is caused by the bacterium Mycobacterium tuberculosis (Mtb). An estimated one-third of the world’s population is infected with TB. Active disease develops in approximately 10 percent of infected people over a lifetime – particularly those with weak immune systems such as infants, the elderly, and people infected with HIV. Globally, cases of active TB have increased significantly since the 1980s due to the AIDS pandemic and the emergence of Mtb strains resistant to standard antibiotic treatment.

In the Science paper, Einstein researchers and collaborators at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, describe a two-drug combination that inhibited both the growth of susceptible laboratory strains and 13 XDR-TB strains isolated from TB patients in laboratory culture medium. The drugs truly work in tandem: one of them (clavulanate) inhibits a bacterial enzyme, beta-lactamase, which normally shields TB bacteria from the other antibiotic (meropenem, a member of the beta-lactam class of antibiotics).

The idea of inhibiting beta-lactamase to make beta-lactam antibiotics effective isn’t new – which is why beta-lactamase inhibitors, such as clavulanate, already exist. The strategy finally proved effective against XDR-TB because Einstein researchers conducted a detailed, methodical investigation of the beta-lactamase enzyme to find the ideal combination of beta-lactamase inhibitor and beta-lactam antibiotic. beta-lactam antibiotics include penicillin, the first antibiotic discovered and one of the safest.

Amoxicillin/clavulanic acid and meropenem have excellent safety profiles and are FDA-approved for adult and pediatric use.

“This is a great example of how, in a collaborative environment, basic, old-fashioned, hypothesis-driven science can lead to timely clinical applications,” said John S. Blanchard, Ph.D., Dan Danciger Professor of Biochemistry at Einstein and senior author of the Science paper, whose research was funded by NIAID.

In parts of Asia, 70 percent of new TB cases are multi-drug resistant, meaning they don’t respond to the two antibiotics most commonly used against TB. Recently, an even greater health threat has emerged: extensively drug-resistant (XDR) bacteria that resist at least four of the drugs used to treat TB and can prove deadly. The cure rate for patients infected with XDR-TB ranges from 12 percent to 60 percent.

XDR-TB is still rare in the United States – 83 cases were documented by the Centers for Disease Control and Prevention between 1993 and 2007. However, worldwide, the figures are much larger and on the rise. In 2004, the World Health Organization (WHO) estimated a half-million people were infected with multi-drug resistant TB, and in some countries the percentage of XDR-TB cases is growing. In the only global TB study to date, the WHO reported in 2008 that 15 percent of multi-drug resistant TB cases in Ukraine, for example, were XDR-TB.

Current TB therapy requires four antibiotics that must be taken for at least six months. “If proven in human subjects, the ability to simplify treatment to just two drugs that work against drug-susceptible, multi-drug resistant and XDR-TB could help patients better adhere to therapy,” said Dr. Blanchard, whose laboratory has conducted pioneering studies of fundamental aspects of antibiotic resistance.

“This discovery could be one of the most promising developments in TB research since the discovery of isoniazid – it is very exciting,” said William Jacobs, Ph.D., referring to the first effective antituberculosis medication discovered in the 1950s. Dr. Jacobs is a Howard Hughes Investigator and professor of microbiology & immunology at Einstein and associate director of the Einstein-Montefiore Center for AIDS Research.

Currently, clavulanate is not commercially available, except in combination with beta-lactam antibiotics, such as amoxicillin. This combination of clavulanate and amoxicillin has been used against other types of bacteria to inhibit beta-lactamase activity and make beta-lactams more effective. But it has rarely been used against TB, which is why the beta-lactamase inhibitor/beta-lactam approach had not been comprehensively analyzed until now.

NIAID researcher Clifton E. Barry, III, Ph.D., a co-author of the new paper, is leading plans to launch a phase two clinical study of the clavulanate potassium-meropenem drug combination in South Korea by the end of 2009 involving approximately 100 TB patients. NIAID investigators are currently working with manufacturers to provide the drugs needed for the trial.

Additionally, as part of a joint collaboration between Montefiore Medical Center, The University Hospital and Academic Medical Center for Albert Einstein College of Medicine, and the Nelson Mandela School of Medicine in Durban, South Africa, a separate trial slated for 2009 will test the potency of the drug combination in a smaller number of TB patients. If the results are successful and funding is available, a trial involving a larger number of XDR-TB patients will be conducted. Montefiore researchers chose South Africa for the clinical studies because of its disproportionately high number of XDR-TB cases. In some areas of South Africa, one in four TB cases is extensively drug resistant.

“We see tremendous potential for treating not only XDR-TB cases, but also routine TB cases,” said Brian Currie, M.D., M.P.H., assistant dean for clinical research, and professor of medicine and of clinical epidemiology and population health at Einstein. Dr. Currie is also vice president and medical director for research at Montefiore. He will serve as U.S. leader for the planned clinical studies in Durban.

With the hope that the meropenem/clavulanate combination proves highly effective in the planned clinical trials, Einstein has filed a patent application on this novel TB treatment method as an incentive for commercial drug manufacturers to support expanded clinical trials and to develop with Einstein an improved combination clavulanate-beta-lactam drug formulation that may be optimized for routine use in TB treatment.

The research and clinical components of these studies will help fulfill the mission of a $22 million Clinical and Translational Science Award given to Einstein and Montefiore by the National Center for Research Resources of the NIH in 2008. The grant supports the new Einstein-Montefiore Institute for Clinical and Translational Research (ICTR) whose goal is to collaboratively expedite the transfer of research discoveries to patient care.

Albert Einstein College of Medicine of Yeshiva University is one of the nation’s premier centers for research, medical education and clinical investigation. It is the home to some 2,000 faculty members, 750 M.D. students, 350 Ph.D. students (including 125 in combined M.D./Ph.D. programs) and 380 postdoctoral investigators. Last year, Einstein received more than $130 million in support from the NIH. This includes the funding of major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Through its extensive affiliation network involving five hospital centers in the Bronx, Manhattan and Long Island – which includes Montefiore Medical Center, The University Hospital and Academic Medical Center for Einstein – the College runs one of the largest post-graduate medical training program in the United States, offering approximately 150 residency programs to more than 2,500 physicians in training.

Source: news-medical.net

Resent studies reported that aspirin inhibited the growth of H. pylori in a dose-dependent manner and significantly affected the activity of virulence factors of H. pylori.

In addition, aspirin increased the susceptibility of H. pylori to antimicrlbials including metronidazole, clarithromycin and amoxicillin. However, the mechanisms remained unknown.

A research team led by Prof. Wang from Peking University First Hospital of China addressed this issue and their results will be published on February 28, 2009 in the World Journal of Gastroenterology .

H. pylori reference strain 26695 and two metronidazole-resistant isolates of H. pylori were included in this study. The effect of aspirin on the permeability of the outer membrane of H. pylori was determined using [7-3H] tetracycline. The effects of aspirin on the expression of OMPs of H. pylori were also determined. Taqman-based real-time quantitative PCR was used to analyze the influence of aspirin on the expression of the related OMPs genes.

They found that the mutations in rdxA gene did not change in metronidazole resistant isolates treated with aspirin. The radioactivity of H. pylori increased when treated with aspirin, indicating that aspirin improved the permeability of the outer membrane of H. pylori . However, the expression of two OMP bands between 55 kDa and 72 kDa altered in the presence of aspirin. The expression of the mRNA of hopA, hopB, hopC, hopD, hopE and hefA, hefB, hefC of H. pylori did not change when treated with aspirin.

Their results indicated that although aspirin increases the susceptibility of H. pylori to metronidazole, it has no effect on the mutations of rdxA gene of H. pylori . Aspirin increases endocellular concentrations of antimicrobials and probably by altering the expression of the outer membrane proteins (OMP) of H. pylori . Their study will help understand the mechanisms of the resistance of H. pylori to antibiotics more intensively and discover a more effective eradication regimen in clinical practice.

Source: www.news-medical.net

Antibiotic prescribing for respiratory illnesses should be standardised across Europe to help reduce inappropriate prescribing and resistance, say experts in a study published.

Antibiotic resistance is a growing problem worldwide. In Europe, 39% of invasive bacteria were resistant to penicillin in 2006 and unnecessary antibiotic prescribing, particularly for respiratory illnesses, has been blamed for increasing antibiotic resistance.

Some evidence also suggests that most antibiotic prescriptions do not help these patients get better any quicker, although the results are still unclear.

So a team of researchers set out to describe variation in antibiotic prescribing for acute cough across Europe, and its impact on recovery.

The study involved 3,402 adults with a new or worsening cough or a possible lower respiratory tract infection. Patients were recruited from 14 primary care research networks in 13 European countries (Wales, England, The Netherlands, Spain, Germany, Hungary, Belgium, Poland, Italy, Sweden, Norway, Finland and Slovakia).

Medical history, existing conditions, symptoms and their management, including antibiotic prescription, and temperature were recorded for each patient. Clinicians then rated the severity of their symptoms using a recognised scoring scale.

Patients also recorded and rated the severity of their symptoms for 28 days using symptom diaries.

Overall, antibiotics were prescribed for 53% of patients, but prescribing ranged from 20% to nearly 90% across the networks. For example, patients in Slovakia, Italy, Hungary, Poland and Wales were at least twice as likely to be prescribed antibiotics than the overall average, while patients in Norway, Belgium and Sweden were at least four times less likely to be prescribed antibiotics than the overall average.

Major differences in the decision whether or not to prescribe an antibiotic remained, even after the researchers adjusted for symptoms, duration of illness, smoking, age, temperature, and existing conditions (co-morbidity).

Furthermore, this variation in antibiotic prescribing was not associated with clinically important differences in patients’ recovery.

There were also marked differences between networks in the choice of antibiotic. Amoxicillin was overall the most common antibiotic prescribed but this ranged from 3% of prescriptions in Norway to 83% in England. These differences may be due to different guidelines and habits in different countries, say the authors.

This is the largest study of its kind, and the results suggest that management of acute cough is an issue that is appropriate for standardised international care pathways promoting conservative antibiotic prescribing, conclude the authors.

Professor Chris Butler, of Cardiff University, who led the study, said: “This international collaborative research showed that the big differences in antibiotic prescribing between countries are not justified on clinical grounds. It therefore identifies a major opportunity for greater standardisation of care across Europe.”

Professor Herman Goossens of the University of Antwerp who coordinates the GRACE Network of Excellence added, “This threat of antibiotic resistance is likely to be more acute as GPs face increasing demands to prescribe antibiotics for acute cough amidst the current global H1N1 flu pandemic. This new evidence should prove instrumental in containing antibiotic prescribing.”

Amoxicillin is a prescription drug that belongs to a classification of drugs called penicillin antibiotics. They are prescribed to treat infections that are caused by bacteria. The penicillin antibiotics kill the bacteria or prevent its growth. Different penicillin antibiotics are used to treat different types of bacterial infections. They can be prescribed in conjunction with other antibiotic medications. The Mayo Clinic notes that none of the penicillin antibiotics are effective in the treatment of colds or the flu. There are, however, some infections for which amoxicillin is typically prescribed.
Typical Uses

Amoxicillin is prescribed for bacterial infections, such as bronchitis, gonorrhea and pneumonia. It is also prescribed as a treatment for infections of the urinary tract, skin, ears, nose and throat. It is also used in combination with other antibiotics in the treatment of H. pylori, which is a bacterium that causes ulcers.
Other Uses

According to the Mayo Clinic, amoxicillin is used in the treatment of certain conditions. These conditions include chlamydia infections in pregnant women. It is also used in the treatment of peptic ulcer disease and gastritis when it is associated with H. pylori. It can also be prescribed in the treatment of lyme disease and typhoid fever.
Anthrax

According to the Centers for Disease Control and Prevention, amoxicillin is used to prevent the development of anthrax disease for people who have been exposed to anthrax when other penicillin antibiotics are not as safe to use. This occurs for women who are pregnant and for children. The use of amoxicillin is only prescribed after test results show that the anthrax bacteria can be killed with penicillin antibiotics.

Source: Liverstrong.com